GLOBAL DESLORATADINE MONTELUKAST MARKET

INTRODUCTION

A combination drug called desloratadine/montelukast is used to treat the symptoms of asthma and allergies. Desloratadine and montelukast are its two active components. Desloratadine is an antihistamine that blocks the action of histamine, a chemical in the body that contributes to numerous allergy symptoms like runny nose, itching, and sneezing.

Leukotriene receptor antagonists, such as montelukast, prevent the body from producing leukotrienes, which are responsible for airway inflammation and constriction.

Hay fever, allergic rhinitis, asthma, and bronchospasm are just a few of the allergic and asthmatic disorders that can be treated with the help of desloratadine and montelukast. It can ease the itchiness, sneezing, runny nose, and congestion brought on by allergies, and also assist in reducing asthma-related airway inflammation and constriction.

The normal dosage of desloratadine/montelukast is one tablet or oral suspension once per day. It's crucial to take the medication exactly as your doctor has advised. Headache, motion sickness, and dizziness are examples of frequent adverse effects. If you have any negative side effects that are bothersome or severe, tell your doctor.

An effective drug for treating the signs and symptoms of allergies and asthma is desloratadine/montelukast. It can ease the itchiness, sneezing, runny nose, and congestion brought on by allergies, and it can also lessen the inflammation and airway narrowing brought on by asthma. Your doctor should be followed when using it, though, and any negative effects should be reported right away.

GLOBAL DESLORATADINE MONTELUKAST MARKET SIZE AND FORECAST

The Global desloratadine montelukast market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.

NEW PRODUCT LAUNCH

Montelukast/Desloratadine is a brand name medication prescribed to treat the symptoms of allergic rhinitis, including congestion, sneezing, and itchy or watery eyes.

It is a combination of two active ingredients, desloratadine (an antihistamine) and montelukast (a leukotriene receptor antagonist), which work together to reduce inflammation and swelling in the airways. This medication is manufactured and distributed by Merck & Co., Inc.

Clarinex-D (desloratadine and montelukast) is a prescription medicine approved for the relief of symptoms of allergic rhinitis (sneezing, runny nose, itchy, watery eyes, and itching of the nose) in adults and children 12 years of age and older.

Clarinex-D combines the antihistamine desloratadine and the leukotriene receptor antagonist montelukast to provide 24-hour relief from seasonal and year-round allergy symptoms.

COMPANY PROFILE

• Teva Pharmaceuticals
• Merck & Co.
• Mylan Pharmaceuticals 
• Sandoz Pharmaceuticals
• GlaxoSmithKline
• Dr. Reddy's Laboratories
• Cipla
• Sun Pharmaceuticals 
• Lupin Pharmaceuticals
• Novartis

THIS REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many desloratadine montelukast are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global desloratadine montelukast  and key vendor selection criteria
3. Where is the desloratadine montelukast manufactured? What is the average margin per unit?
4. Market share of Global desloratadine montelukast  market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global desloratadine montelukast  in-house
6. key predictions for next 5 years in Global desloratadine montelukast  market
7. Average B-2-B desloratadine montelukast  market price in all segments
8. Latest trends in desloratadine montelukast  market, by every market segment
9. The market size (both volume and value) of the desloratadine montelukast market in 2023-2030 and every year in between?
10. Production breakup of desloratadine montelukast  market, by suppliers and their OEM relationship